| scholarly article | Q13442814 |
| P50 | author | Juan José Lasarte | Q40687778 |
| P2093 | author name string | C Mansilla | |
| C Gamazo | |||
| I Tamayo | |||
| J M Irache | |||
| J Ochoa-Repáraz | |||
| P2860 | cites work | Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 |
| MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. | Q30365117 | ||
| Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. | Q30368742 | ||
| Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. | Q30379655 | ||
| Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. | Q33282108 | ||
| Vaccine adjuvants: current state and future trends | Q34358206 | ||
| Recognition of pathogen-associated molecular patterns by TLR family | Q35044748 | ||
| The role of Toll-like receptor 2 in microbial disease and immunity | Q35134715 | ||
| Vaccination strategies. An overview | Q35134728 | ||
| Activation of dendritic cells: translating innate into adaptive immunity | Q35634014 | ||
| Modulating vaccine responses with dendritic cells and Toll-like receptors | Q35826412 | ||
| Aluminium compounds for use in vaccines | Q35915759 | ||
| Schistosome larvae stimulate macrophage cytokine production through TLR4-dependent and -independent pathways. | Q35946159 | ||
| Toll-like receptors, endogenous ligands, and systemic autoimmune disease. | Q36079856 | ||
| Targeting the innate immune response with improved vaccine adjuvants | Q36090194 | ||
| Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies | Q36324857 | ||
| Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors | Q36726933 | ||
| Cooperation of Toll-like receptor signals in innate immune defence | Q36743540 | ||
| Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists | Q36811131 | ||
| The perfect mix: recent progress in adjuvant research | Q36844715 | ||
| MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? | Q36986520 | ||
| Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome | Q37070610 | ||
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 | ||
| A vault nanoparticle vaccine induces protective mucosal immunity | Q37165790 | ||
| Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens | Q37191759 | ||
| Delivery systems: a vaccine strategy for overcoming mucosal tolerance? | Q37354182 | ||
| Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer | Q37387913 | ||
| Optimized subunit vaccine protects against experimental leishmaniasis | Q37439440 | ||
| Innate immune sensing and activation of cell surface Toll-like receptors | Q37506815 | ||
| Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination | Q37762031 | ||
| The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria | Q39609889 | ||
| Molecular events in the activation of B cells and macrophages by a non-microbial TLR4 agonist, G1-4A from Tinospora cordifolia | Q39854132 | ||
| Streptococcus suis bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. | Q40015954 | ||
| Bioadhesive mannosylated nanoparticles for oral drug delivery | Q40278175 | ||
| Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma--a new vaccination strategy | Q40316527 | ||
| Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes | Q40641430 | ||
| Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids | Q40673400 | ||
| Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers | Q40721665 | ||
| TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. | Q42132922 | ||
| Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2. | Q43409240 | ||
| Not "molecular patterns" but molecules | Q43833840 | ||
| Encapsulation of antigenic extracts of Salmonella enterica serovar. Abortusovis into polymeric systems and efficacy as vaccines in mice. | Q43962321 | ||
| Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates | Q44185143 | ||
| Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. | Q44755402 | ||
| The involvement of tumor necrosis factor in immunity to Salmonella infection | Q44936270 | ||
| Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. | Q45962430 | ||
| Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. | Q45985497 | ||
| Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. | Q46350946 | ||
| Salmonella-like bioadhesive nanoparticles | Q46560166 | ||
| Synthesis of beta-(1-->4)-oligo-D-mannuronic acid neoglycolipids | Q46898321 | ||
| Humoral immune response in hens naturally infected with Salmonella Enteritidis against outer membrane proteins and other surface structural antigens | Q47312399 | ||
| Importance of the major Fli C antigenic site of Salmonella enteritidis as a subunit vaccine antigen | Q50060876 | ||
| Clinical development of TLR agonists as adjuvants: "post-alum adjuvant" candidates may reach beyond their intended purpose. | Q50649156 | ||
| Development of a novel vaccine delivery system based on Gantrez nanoparticles. | Q51117082 | ||
| Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells. | Q53488746 | ||
| Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens | Q57216501 | ||
| Evaluation of particulate acellular vaccines against Brucella ovis infection in rams | Q59276365 | ||
| Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides | Q74216320 | ||
| The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo | Q79485051 | ||
| Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do | Q80625739 | ||
| P433 | issue | 9 | |
| P921 | main subject | nanoparticle | Q61231 |
| toll-like receptor | Q408004 | ||
| P304 | page(s) | 1356-1362 | |
| P577 | publication date | 2010-07-14 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation | |
| P478 | volume | 17 |
| Q26744352 | A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements |
| Q37965725 | Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q38131659 | Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. |
| Q30426452 | Biomedical Applications of Biodegradable Polymers |
| Q39259629 | Current state and challenges in developing oral vaccines |
| Q34057755 | Immunogenicity of peanut proteins containing poly(anhydride) nanoparticles |
| Q39113247 | Intranasal delivery of nanoparticle-based vaccines. |
| Q44348398 | Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine |
| Q92230033 | Mannosylated Nanoparticles for Oral Immunotherapy in a Murine Model of Peanut Allergy |
| Q41915826 | Materials design at the interface of nanoparticles and innate immunity. |
| Q46246924 | Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections |
| Q28396375 | Metal-Based Nanoparticles and the Immune System: Activation, Inflammation, and Potential Applications |
| Q38330161 | Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization |
| Q26748776 | Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems |
| Q38796320 | Modifying the tumor microenvironment using nanoparticle therapeutics |
| Q42275411 | Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine |
| Q84938205 | Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice |
| Q37890639 | Nanomedicine: novel approaches in human and veterinary therapeutics |
| Q38257645 | Nanoparticle based-immunotherapy against allergy. |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q26825418 | Nanoparticulate adjuvants and delivery systems for allergen immunotherapy |
| Q38102471 | Nanovaccines and their mode of action. |
| Q38978845 | New pharmaceutical approaches for the treatment of food allergies. |
| Q38586079 | Nucleic acid vaccination strategies against infectious diseases. |
| Q47410379 | Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis. |
| Q58385253 | Particulate transepithelial drug carriers: barriers and functional polymers |
| Q37860707 | Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines |
| Q35592058 | Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice |
| Q84301195 | Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators |
| Q38693411 | Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen |
| Q37010485 | Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. |
| Q28083076 | Safety of Nanoparticles in Medicine |
| Q38725470 | Salmonella Vaccination in Pigs: A Review. |
| Q58559836 | Single dose of polyanhydride particle-based vaccine generates potent antigen-specific antitumor immune responses |
| Q27027780 | Stimulating antitumor immunity with nanoparticles |
| Q59798948 | Surface engineered polyanhydride-based oral Salmonella subunit nanovaccine for poultry |
| Q38722460 | The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response |
| Q38101310 | The recognition of biomaterials: pattern recognition of medical polymers and their adsorbed biomolecules. |
Search more.